- Home
- MVO vs TPST Comparison
MVO vs TPST Comparison
Compare MVO & TPST Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | MVO | TPST |
|---|---|---|
| Founded | 2006 | 2011 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Oil & Gas Production | Biotechnology: Pharmaceutical Preparations |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 26.3M | 26.2M |
| IPO Year | N/A | 2012 |
Fundamental Metrics
Financial Performance| Metric | MVO | TPST |
|---|---|---|
| Price | $0.63 | $0.97 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $11.00 |
| AVG Volume (30 Days) | ★ 397.9K | 98.1K |
| Earning Date | 01-01-0001 | 05-08-2026 |
| Dividend Yield | ★ 17.46% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ 1.46 | N/A |
| Revenue | N/A | ★ $295,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $0.43 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $0.62 | $0.94 |
| 52 Week High | $6.19 | $12.22 |
Technical Indicators
Market Signals| Indicator | MVO | TPST |
|---|---|---|
| Relative Strength Index (RSI) | 26.54 | 31.54 |
| Support Level | N/A | N/A |
| Resistance Level | $1.86 | $2.48 |
| Average True Range (ATR) | 0.18 | 0.07 |
| MACD | -0.05 | 0.01 |
| Stochastic Oscillator | 2.48 | 15.88 |
Price Performance
Historical ComparisonAbout MVO MV Oil Trust Units of Beneficial Interests
MV Oil Trust is a statutory trust. The trust was created to acquire and hold the net profits interest for the benefit of the Trust unitholders.
About TPST Tempest Therapeutics Inc.
Tempest Therapeutics Inc is a late-stage develpment biotechnology company developing small molecule therapeutics to treat cancer through mechanisms that directly kill tumor cells and activate tumor-specific immunity. Its clinical-stage therapeutic product candidates are TPST-1120 and TPST-1495 which are clinical-stage molecules designed to inhibit their respective targets. Company's small-molecule product candidate, amezalpat (previously known as TPST-1120), has completed a Phase 2 study in first-line hepatocellular carcinoma and the second small-molecule product candidate is TPST-1495, plans to initiate a Phase 2 study for in familial adenomatous polyposis.